Novyra Pharmachem Reports Q2 Results with Widening Net Loss Despite Revenue Surge
Bansisons Tea Industries Ltd · Financial Result · 02 Nov 2026, 11:21 pm
Novyra Pharmachem Reports Q2 Results with Widening Net Loss Despite Revenue Surge Novyra Pharmachem reported total revenue of ₹426.78 lakh for the quarter ended 30th Sep'26, jumping sharply from ₹3.31 lakh YoY and ₹172.61 lakh QoQ, driven primarily by ₹423.08 lakh from its Pharma segment. Despite top-line expansion, total expenses rose to ₹430.10 lakh due to ₹414.02 lakh in stock purchases, leading to a net loss of ₹3.32 lakh compared to a profit of ₹0.10 lakh YoY and a loss of ₹1.99 lakh QoQ. Diluted EPS stood at ₹(0.05).
Original exchange filing (PDF)
More announcements from Bansisons Tea Industries Ltd
- Unaudited financial results for the quarter ended September 30, 2026 · 02 Nov 2026
- Novyra Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve Un-Audited Financial Results .... · 02 Nov 2026
- Intimation under Reg 30 · 24 Sept 2026
- Reg 30 · 22 Aug 2026
- Quarterly Results June 30, 2026 · 14 Aug 2026
- Quarterly Results June 30, 2026 · 14 Aug 2026
- Bansisons Tea Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Quarterly Results June 30, 2026 · 14 Aug 2026
- Change of Website · 04 Aug 2026
